These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30625345)

  • 1. Cardioprotective actions of relaxin.
    Martin B; Romero G; Salama G
    Mol Cell Endocrinol; 2019 May; 487():45-53. PubMed ID: 30625345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-fibrotic actions of relaxin are mediated through AT
    Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
    FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding relaxin signalling at the cellular level.
    Valkovic AL; Bathgate RA; Samuel CS; Kocan M
    Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relaxin abrogates genomic remodeling of the aged heart.
    Romero G; Salama G
    Vitam Horm; 2021; 115():419-448. PubMed ID: 33706957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties.
    Beiert T; Knappe V; Tiyerili V; Stöckigt F; Effelsberg V; Linhart M; Steinmetz M; Klein S; Schierwagen R; Trebicka J; Roell W; Nickenig G; Schrickel JW; Andrié RP
    Int J Cardiol; 2018 Jan; 250():21-28. PubMed ID: 29169754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
    Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
    Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin reverses inflammatory and immune signals in aged hearts.
    Martin B; Gabris-Weber BA; Reddy R; Romero G; Chattopadhyay A; Salama G
    PLoS One; 2018; 13(1):e0190935. PubMed ID: 29346407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.
    Sasser JM
    Kidney Int; 2014 Jul; 86(1):9-10. PubMed ID: 24978374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity.
    Praveen P; Wang C; Handley TNG; Wu H; Samuel CS; Bathgate RAD; Hossain MA
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties.
    Beiert T; Tiyerili V; Knappe V; Effelsberg V; Linhart M; Stöckigt F; Klein S; Schierwagen R; Trebicka J; Nickenig G; Schrickel JW; Andrié RP
    Biochem Biophys Res Commun; 2017 Aug; 490(3):643-649. PubMed ID: 28634079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
    Mookerjee I; Hewitson TD; Halls ML; Summers RJ; Mathai ML; Bathgate RA; Tregear GW; Samuel CS
    FASEB J; 2009 Apr; 23(4):1219-29. PubMed ID: 19073841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The actions of relaxin on the human cardiovascular system.
    Sarwar M; Du XJ; Dschietzig TB; Summers RJ
    Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease.
    Samuel CS; Du XJ; Bathgate RA; Summers RJ
    Pharmacol Ther; 2006 Nov; 112(2):529-52. PubMed ID: 16814863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.
    Ng HH; Shen M; Samuel CS; Schlossmann J; Bennett RG
    Mol Cell Endocrinol; 2019 May; 487():59-65. PubMed ID: 30660699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
    Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
    Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
    Grampp S; Goppelt-Struebe M
    Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-fibrotic actions of relaxin.
    Samuel CS; Royce SG; Hewitson TD; Denton KM; Cooney TE; Bennett RG
    Br J Pharmacol; 2017 May; 174(10):962-976. PubMed ID: 27250825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes.
    Wong SE; Samuel CS; Kelly DJ; Zhang Y; Becker GJ; Hewitson TD
    Protein Pept Lett; 2013 Sep; 20(9):1029-38. PubMed ID: 23343143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
    Bani-Sacchi T; Bigazzi M; Bani D; Mannaioni PF; Masini E
    Br J Pharmacol; 1995 Sep; 116(1):1589-94. PubMed ID: 8564223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxin's physiological roles and other diverse actions.
    Sherwood OD
    Endocr Rev; 2004 Apr; 25(2):205-34. PubMed ID: 15082520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.